Etigilimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEtigilimab
Drug Alias NameAnti-TIGIT monoclonal antibodyOMP-313M32
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisFallopian Tube Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncomed Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMereo BiopharmaThe University Of Texas MD Anderson Cancer CenterCelgene Corp
Inactive CompaniesOncomed Pharmaceuticals Inc
Active IndicationsSolid tumoursFallopian Tube NeoplasmsOvarian Neoplasms +[5] 
Inactive IndicationsNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A